| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
GlucoTrack, Inc.$0.3
+0.01 (+2.27%)
F 2Pipeline Score MedTech · Clinical
Market Cap
3.13 M
EPS
-20.88
P/E Ratio
-
Value Trade
359.96 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.13 M
Operating CF
-4.05 M
Total Assets
4.36 M
Total Liabilities
5.21 M
Equity
-851.00 K
D/E Ratio
12,345
-24.24 %
Week
-35.91 %
1 Month
-69.17 %
3 Month
-89.8 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
3.93 M
Monthly Burn
1.35 M
Runway
0.4 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
246.34 K
52 Week Range
0.43 - 15.90
% held by Insiders
18.72 %
% held by Institutions
3.72 %
Enterprise Value
2.79 M
Total Shares
6.26 M
Short %
38.1 %
Float Shares
6.23 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 4%
Micro Cap (rank 877 of 913)
Percentile RankGlucoTrack, Inc. has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Glucotrack Continuous Blood Glucose Monitor | diabetes management | — | 2026-03-10 | positive results from the first-in-human study | Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit Read More | |
Glucotrack Continuous Blood Glucose Monitor | diabetes management | — | 2026-03-10 | positive results from the first-in-human study | Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit Read More | |
Glucotrack Continuous Blood Glucose Monitor | diabetes management | — | 2026-03-10 | positive results from the first-in-human study | Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GCTK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GCTK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GCTKGlucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
Glucotrack, Inc. has completed a bridge financing to support its strategic growth objectives following its business combination with Lōkahi Therapeutics. E.F. Hutton & Co. acted as the exclusive financial advisor for this financing. The funds will enhance the company's financial flexibility and support ongoing initiatives, including the advancement of Lōkahi's ai² methodology and its product development efforts.
Read more →GCTKUPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Glucotrack, Inc. has successfully completed its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed platform aimed at advancing healthcare assets. Lōkahi will control the combined entity, utilizing Glucotrack’s infrastructure to enhance growth. The transaction includes a planned private placement to bolster capital and support ongoing operations.
Read more →GCTKGlucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Glucotrack, Inc. has successfully completed its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed platform aimed at advancing healthcare assets. Lōkahi will control the combined entity, utilizing Glucotrack's infrastructure for growth. The merger is supported by a private placement financing to bolster capital. Leadership changes have been made to guide the new organization.
Read more →GCTKGlucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
Glucotrack, Inc. announced that the USPTO has issued a Notice of Allowance for its patent application related to its continuous blood glucose monitoring (CBGM) platform. This patent expands the protection of the company's technology as it moves towards commercialization. The CBGM system is designed for long-term, implantable glucose monitoring without wearable components, providing real-time glucose readings directly from blood.
Read more →GCTK▲ +18.9%on this news· ran to +32% by day 3
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions
Glucotrack, Inc. will present its innovative implantable continuous blood glucose monitoring technology at the ADA 2026 Scientific Sessions in New Orleans. The presentation will showcase advancements in CGM technology that promise improved accuracy and longevity. With an IDE submission to the FDA already in progress, Glucotrack aims to engage with the diabetes community regarding future developments.
Read more →GCTK▲ +18.9%on this news· ran to +32% by day 3shared move
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions
Glucotrack, Inc. will present its implantable continuous blood glucose monitoring technology at the ADA 2026 Scientific Sessions. The presentation will focus on advancements in CGM technology that offer accurate blood measurements and extended sensor longevity. The company has submitted an Investigational Device Exemption application to the FDA, marking a significant step toward clinical studies.
Read more →GCTKGlucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Glucotrack, Inc. reported its first quarter 2026 financial results, highlighting the submission of an Investigational Device Exemption (IDE) application to the FDA aimed at initiating a U.S. clinical study for its implantable continuous blood glucose monitoring technology. The company noted a reduction in net loss compared to the previous year and emphasized advancements in their product development, supported by peer-reviewed studies. Additionally, Glucotrack has strengthened its financial position through debt reduction and capital funding. The company aims to initiate clinical studies in the second half of 2026.
Read more →GCTKGlucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
Glucotrack, Inc. has submitted an Investigational Device Exemption (IDE) application to the FDA to begin a clinical study on its continuous blood glucose monitoring technology. This submission marks a crucial step in the company's efforts to advance their implantable system designed for long-term monitoring without an on-body wearable. The technology aims to enhance convenience for diabetes patients by eliminating frequent sensor changes. Following FDA review and approval, Glucotrack intends to proceed with clinical trials to collect necessary data for regulatory approval.
Read more →GCTK▼ -7.3%on this news· ran to -21% by day 3
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
Glucotrack, Inc. has announced the publication of a peer-reviewed study in The Journal of Diabetes Research, showcasing the long-term accuracy and stability of its continuous blood glucose monitoring (CBGM) technology. The study, conducted on an ovine model, demonstrated an impressive Mean Absolute Relative Difference (MARD) of 6.8% and reported no adverse safety events. This research highlights the reliability of Glucotrack's system over a period of 240 days, reinforcing the company's confidence as it moves towards FDA approval. The findings are part of the growing body of evidence supporting the advantages of Glucotrack's innovative monitoring solutions for diabetes management.
Read more →GCTKGlucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
Glucotrack, Inc. announced the publication of a peer-reviewed study in the IEEE Sensors Journal, showcasing the long-term stability of its implantable continuous blood glucose monitoring technology. This research presents the first comprehensive year-long assessment of glucose oxidase enzyme decay, bolstering the company's confidence in their device's design. The study was conducted in partnership with TTP, emphasizing the advanced development of Glucotrack’s CBGM system. The company aims to submit an Investigational Device Exemption to the FDA in the near future.
Read more →GCTK▼ -23.6%on this news· ran to -34% by day 1
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Glucotrack, Inc. announced its financial results for the fourth quarter and full year ending December 31, 2025, detailing significant developments in its implantable continuous blood glucose monitoring technology. The company is preparing to submit an Investigational Device Exemption to the FDA, targeting a launch for U.S. clinical trials in the second half of 2026. It also highlighted an increase in its intellectual property portfolio through newly issued patents. Despite a decrease in its annual net loss compared to the previous year, the company continues to operate with significant financial challenges, reflecting increased R&D and administrative expenses.
Read more →GCTK▼ -9.2%on this news· ran to -31% by day 1shared move
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Glucotrack, Inc. is set to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026 for its continuous blood glucose monitoring technology. The company has made significant progress, including completing its first in-human study in Brazil and initiating a follow-up study in Australia. With a solid operational foundation and key patents secured, Glucotrack aims to address the unmet needs of diabetes management in the U.S.
Read more →GCTKGlucotrack to Present at LSI USA ’26 Medtech Innovation Summit
Glucotrack, Inc. will present its continuous blood glucose monitor technology at the LSI USA '26 Medtech Innovation Summit. CEO Paul V. Goode will discuss positive first-in-human study results and outline the company's regulatory and commercialization strategies. The device aims to enhance diabetes management with a user-friendly approach.
Read more →GCTKGlucotrack to Present at LSI USA ’26 Medtech Innovation Summit
Glucotrack, Inc. will present its continuous blood glucose monitor technology at the LSI USA '26 Medtech Innovation Summit. CEO Paul V. Goode will discuss the positive results from the first-in-human study and outline the company's regulatory and commercialization strategies. The summit aims to connect with investors and partners to advance diabetes management solutions.
Read more →GCTK▼ -33.4%on this news· ran to -48% by day 3
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
Glucotrack, Inc. has received approval from the USPTO for three patents related to its continuous blood glucose monitoring (CBGM) platform. These patents protect key technologies that enhance the device's competitive edge as it moves towards commercialization. The CBGM system is designed for long-term use, providing a more convenient glucose monitoring solution for diabetes patients.
Read more →GCTK▼ -33.4%on this news· ran to -48% by day 3shared move
GLUCOTRAC K ANNOUNCES USPTO APPROVAL FOR ISSUANCE OF PATENTS FOR PROPRIETARY CBGM PLATFORM Rutherford, NJ
Glucotrack, Inc. has announced the approval of three patents by the US Patent and Trademark Office for its proprietary continuous blood glucose monitoring (CBGM) platform. These patents enhance the company's intellectual property position as it develops a fully implantable CBGM system. The innovation promises to offer long-term, accurate blood glucose monitoring without the need for a wearable component. The company is currently navigating the challenges of further clinical testing and securing necessary regulatory approvals for commercialization.
Read more →GCTK▼ -10.9%on this news
Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor
Glucotrack, Inc. has announced a private placement agreement with an institutional investor, raising approximately $4.0 million through the sale of shares and warrants. The effective price per share is set at $3.87, and the closing is anticipated by December 31, 2025. Proceeds will be used for working capital and corporate needs.
Read more →GCTKGlucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights
Glucotrack, Inc. announced its financial results for the third quarter of 2025, highlighting significant progress in its corporate objectives. The company has secured additional funding to support its operations until March 2026 and has expanded its clinical advisory team with a key appointment. Looking forward, Glucotrack plans to submit an Investigational Device Exemption to the FDA for its continuous blood glucose monitor technology in Spring 2026, while continuing clinical developments in the U.S. and Australia. Despite reporting a net loss, the company is committed to advancing its innovative diabetes management technologies.
Read more →GCTKE xhibit 99.1 Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring
Glucotrack, Inc. (GCTK) reported its financial results for Q3 2025 and outlined key corporate developments. The company plans to submit an Investigational Device Exemption to the FDA for its continuous blood glucose monitoring technology in Spring 2026. Recent highlights include securing funding and expanding its clinical advisory team with a new appointment in pain management. Despite operational progress, the company also experienced a loss in Q3, signaling ongoing financial challenges.
Read more →GCTK▼ -5.9%on this news
Glucotrack, Inc. Encourages Shareholders to Vote
Glucotrack, Inc. is urging shareholders to vote at a Special Meeting on November 7, 2025, regarding an Equity Purchase Agreement with Sixth Borough Capital Fund. The company emphasizes the importance of every vote and provides various methods for shareholders to cast their votes. The Board unanimously recommends voting 'FOR' all proposals to ensure full representation.
Read more →GCTKGlucotrack, Inc. Encourages Shareholders to Vote The Special Meeting of Shareholders reconvenes on
Glucotrack, Inc. (GCTK) announced that it will reconvene its Special Meeting of Shareholders on November 7, 2025, to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund. The company urges all shareholders to vote as soon as possible to ensure their shares are represented. The Board of Directors unanimously recommends approval of all proposals and emphasizes the importance of participation in the voting process. At stake is an agreement that allows the issuance of over 20% of the company's stock through a $20 million deal.
Read more →GCTKGlucotrack, Inc. Reminds Shareholders to Vote The Special Meeting of Shareholders held on
Glucotrack, Inc. is reminding shareholders to vote in a Special Meeting scheduled for October 31, 2025. The meeting will address an Equity Purchase Agreement with Sixth Borough Capital Fund. The company encourages shareholders who hold stock in multiple accounts to vote for each separately to ensure full representation. The Board of Directors has recommended voting 'FOR' all proposals presented.
Read more →GCTKGlucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team
Glucotrack, Inc. has appointed Dr. Usman Latif to its clinical advisory team to enhance its glucose monitoring applications for Painful Diabetic Neuropathy. Dr. Latif brings extensive expertise in pain management and neuromodulation, which will support the integration of glucose sensing into spinal cord stimulators. This advancement aims to improve care for the millions affected by diabetic neuropathy.
Read more →GCTK▲ +9.9%on this newsshared move
Glucotrack, Inc. Reminds Shareholders to Vote
Glucotrack, Inc. is urging shareholders to participate in an upcoming Special Meeting scheduled for October 31, 2025, regarding an Equity Purchase Agreement with Sixth Borough Capital Fund. Shareholders of record as of September 23, 2025, will have the opportunity to vote, and the company emphasizes the importance of every vote. Voting can be done conveniently via telephone or online, and shareholders are encouraged to ensure they represent all their accounts.
Read more →GCTK▲ +5.2%on this news· ran to +129% by day 1
Glucotrack to Participate in the Q3 Virtual Investor Summit
Glucotrack, Inc. (GCTK) will present at the Q3 Virtual Investor Summit on September 16-17, 2025. CEO Paul V. Goode will lead the presentation and engage in one-on-one meetings with investors. The company is focused on developing an implantable continuous blood glucose monitoring system for diabetes management, currently in the investigational stage.
Read more →GCTKGlucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Glucotrack, Inc. reported its financial results for Q2 2025, highlighting significant advancements in its continuous blood glucose monitoring technology. The company is set to begin patient trials in Australia by Q3 2025 and plans to submit an Investigational Device Exemption to the FDA in Q4 2025. Despite an increase in net loss, Glucotrack's cash position has improved, allowing it to fund operations through 2025.
Read more →GCTKGlucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology
Glucotrack, Inc. has appointed Dr. David S. Hirsh as Medical Director of Cardiology to lead clinical initiatives for its Continuous Blood Glucose Monitor (CBGM). Dr. Hirsh's expertise in interventional cardiology will support the company's clinical development programs. His role will involve site selection, physician education, and protocol compliance as Glucotrack advances its clinical trials.
Read more →GCTKGlucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting
Glucotrack, Inc. will exhibit its Continuous Blood Glucose Monitor at the 2025 ADCES Annual Meeting in Phoenix, AZ. The device represents a significant advancement in diabetes management, offering a long-term, implantable solution that measures glucose levels directly from the blood. The company aims to discuss its clinical progress and the potential of its technology with diabetes care leaders.
Read more →GCTKGlucotrack Announces Repurchase of Series A Warrants
Glucotrack, Inc. has repurchased over 90% of its Series A Warrants as part of its capital strategy. This move is seen as a demonstration of the company's confidence in its long-term implantable continuous blood glucose monitoring system. CEO Paul Goode emphasized the importance of this repurchase in strengthening the company's capital structure and delivering shareholder value.
Read more →GCTK▲ +26.2%on this news
Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
Glucotrack, Inc. announced positive results from its first-in-human study of a Continuous Blood Glucose Monitor (CBGM) at the ADA 85th Scientific Sessions. The study achieved all endpoints, showing a Mean Absolute Relative Difference (MARD) of 7.7% and a 99% data capture rate. The device demonstrated excellent safety and accuracy, paving the way for further clinical trials.
Read more →GCTK▲ +26.2%on this newsshared move
Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
Glucotrack, Inc. announced positive results from its first-in-human study of a Continuous Blood Glucose Monitor (CBGM) at the ADA's 85th Scientific Sessions. The study showed a Mean Absolute Relative Difference (MARD) of 7.7% and a 99% data capture rate, validating the device's safety and performance. The company plans to initiate a long-term feasibility study in Q3 2025.
Read more →GCTK▼ -33.8%on this news
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
Glucotrack, Inc. has announced a 1-for-60 reverse stock split effective June 16, 2025, following shareholder approval. This action aims to ensure compliance with Nasdaq's minimum bid price requirement and attract institutional investors. The company will continue trading under the ticker GCTK, with adjustments made automatically for stockholders.
Read more →GCTKGlucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
Glucotrack, Inc. will present its first-in-human trial data for its implantable continuous blood glucose monitoring system at the ADA's 85th Scientific Sessions in June 2025. The presentation will highlight the safety and performance of this innovative technology, which aims to redefine diabetes management by providing direct blood glucose measurements without the need for wearables. The company is optimistic about the future of its CBGM system.
Read more →GCTKGlucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
Glucotrack, Inc. announced it will showcase its next-generation continuous blood glucose monitoring system at the American Diabetes Association's 85th Scientific Sessions, set for June 20-23, 2025, in Chicago. The company will present safety and performance data from its first-in-human trial of their implantable system, highlighting its design that allows glucose monitoring directly from the blood without a wearable component. The technology aims to redefine diabetes management with real-time accuracy over a three-year period, minimizing disruptions for users. Glucotrack's attendance at the scientific sessions marks a significant step forward in their development efforts.
Read more →GCTKGlucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
Glucotrack, Inc. has announced the election of Dr. Victoria E. Carr-Brendel to its Board of Directors, effective May 22, 2025. Her extensive background in medical devices, particularly in implantable technologies, is expected to enhance the board's effectiveness. Dr. Carr-Brendel's previous leadership roles at notable companies indicate a strong potential for advancing Glucotrack's continuous blood glucose monitoring (CBGM) technology. This innovative system aims to offer a more convenient and less intrusive glucose monitoring solution for diabetes patients as it progresses towards commercialization.
Read more →GCTK▼ -5.1%on this newsshared move
AMENDMENT TO GLUCOTRACK, INC. 2024 EQUITY INCENTIVE PLAN This Amendment (this " Amendment ") to the Glucotrack, Inc. 2024 Equity Incentive Plan, as amended (the " Plan ") is dated as of
Glucotrack, Inc. announced an amendment to its 2024 Equity Incentive Plan, which aims to increase the maximum aggregate number of shares that may be issued under the plan to 7,500,000. This amendment is subject to shareholder approval and is intended to align with the company's goals and the interests of its shareholders. The amendment will take effect on May 22, 2025, and underscores the company's commitment to effective management and strategic growth.
Read more →GCTKGlucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development
Glucotrack, Inc. has formed a Patient Advisory Board (PAB) to guide the development of its Continuous Blood Glucose Monitor (CBGM). The board comprises individuals with firsthand diabetes management experiences and aims to integrate patient insights into the technology's development. Following a successful initial clinical study, the PAB will meet regularly to provide input on challenges faced by diabetes patients. The CBGM offers a long-term, implantable solution for blood glucose monitoring, designed to deliver accurate readings without the need for a wearable component.
Read more →GCTKGlucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Glucotrack, Inc. has reported its financial results for the first quarter of 2025, highlighting significant progress in its continuous blood glucose monitor (CBGM) technology. The company has received ethical approval to begin a long-term clinical study in Australia and expects FDA Investigational Device Exemption approval later this year. The financial report indicates a net loss increase compared to the prior year, emphasizing the company's challenges in maintaining financial stability as it develops its technology. Despite these hurdles, Glucotrack continues to forge partnerships to enhance its clinical research and data insights.
Read more →GCTKGlucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor
Glucotrack, Inc. has received ethical approval for a long-term clinical study of its continuous blood glucose monitor (CBGM) from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee. The study aims to enroll 30 participants with type 1 and type 2 diabetes to evaluate the CBGM's safety and performance over one year, with potential extension to three years. The device directly measures blood glucose, which may offer a more accurate and convenient monitoring solution compared to traditional methods. Enrollment is set to begin by July, following notification to Australia's Therapeutic Goods Administration.
Read more →GCTK▲ +9.3%on this news
GLUCOTRACK ESTABLISHES PATIENT ADVISORY BOARD TO INFORM DIABETES TECHNOLOGY DEVELOPMENT Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology Rutherford,
Glucotrack, Inc. (NASDAQ: GCTK) has established a Patient Advisory Board (PAB) to facilitate the development of its Continuous Blood Glucose Monitor (CBGM). The board consists of diabetes community advocates to provide insights on patient experiences, ensuring that product development meets real-world needs. The first meeting was held on May 3, 2025, marking a significant step in the company’s efforts to incorporate authentic patient perspectives into its technology. The CBGM aims to offer a long-term, implantable solution for accurate glucose monitoring over a period of three years, eliminating the inconvenience of wearable devices.
Read more →GCTKGlucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas
Glucotrack, Inc. has announced its participation in the FORGETDIABETES initiative aimed at developing a bionic pancreas for type 1 diabetes management. The project, funded by the EU's Horizon 2020 program, seeks to create an automated insulin delivery system with the potential to simplify diabetes treatment significantly. Glucotrack’s Continuous Blood Glucose Monitor will play a crucial role in this project, providing real-time glucose levels to optimize insulin delivery. The initiative aims to reduce the burdens associated with diabetes and improve the quality of life for those affected by the condition.
Read more →GCTK▼ -6.6%on this news· ran to -27% by day 3
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Glucotrack, Inc. announced a collaboration with OneTwo Analytics AB to analyze clinical study data for its Continuous Blood Glucose Monitor (CBGM). This partnership aims to utilize AI and machine learning to enhance the evaluation of the device's performance. The CBGM provides direct blood glucose measurements, offering significant improvements over traditional monitors. The collaboration is intended to empower better decision-making for both healthcare providers and patients with diabetes. This move signifies a strategic step in Glucotrack's commitment to innovation in diabetes management.
Read more →GCTK▼ -6.6%on this news· ran to -27% by day 3
E xhibit 99.1 GLUCOTRACK AND ONETWO ANALYTICS TO COLLABORATE FOR CLINICAL STUDY ANALYSIS ON ITS CONTINUOUS BLOOD GLUCOSE MONITOR Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Bloo
Glucotrack (GCTK) has announced a collaboration with OneTwo Analytics to analyze clinical study data for its Continuous Blood Glucose Monitor (CBGM). This partnership will utilize advanced AI-driven analytics to derive critical insights into the device's performance and clinical value. The CBGM is designed as a long-term implantable device, offering real-time blood glucose monitoring without the lag time associated with traditional methods. Both companies aim to transform diabetes management through this innovative collaboration.
Read more →GCTK▼ -14.9%on this newsshared move
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
Glucotrack reported significant advancements over the year 2024, transitioning from a preclinical to a clinical stage company and making progress in its continuous blood glucose monitoring technology. The company completed its first human clinical study successfully, achieving all primary endpoints without serious device-related issues. Financially, while Glucotrack secured $16.3 million through funding rounds, its net loss increased substantially compared to the previous year. Looking ahead, Glucotrack is preparing for key FDA approvals and additional studies in 2025 to advance its innovative technology.
Read more →GCTK▲ +8.9%on this news· ran to -24% by day 3
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
Glucotrack, Inc. announced that it will present results from its first-in-human trial of a continuous blood glucose monitoring system at the 2025 ATTD conference. The trial demonstrated safety and promising performance, highlighting the device's ability to measure glucose directly from blood. This innovative implantable device aims to improve diabetes management without external components.
Read more →GCTK▲ +8.9%on this news· ran to -24% by day 3shared move
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
Glucotrack, Inc. announced that it will present data from its first-in-human trial of a continuous blood glucose monitoring (CBGM) system at the 2025 ATTD conference in Amsterdam. The results highlight the safety, feasibility, and promising performance of the CBGM technology, which measures glucose directly from the blood for enhanced accuracy without requiring on-body wearables. This innovative approach could represent a significant advancement in diabetes management. Detailed findings will be shared at the conference and subsequently accessible on the company's website.
Read more →GCTK▲ +5.2%on this news
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member
Glucotrack, Inc. has appointed Dr. Guillermo Umpierrez as a new member of its Medical Advisory Board. Dr. Umpierrez is a well-respected figure in diabetes care with extensive clinical and research experience. His expertise is expected to enhance the development of Glucotrack's novel Continuous Blood Glucose Monitoring (CBGM) technology as the company prepares for human clinical trials. The CBGM system promises to offer real-time, less intrusive glucose monitoring solutions for diabetes patients.
Read more →GCTK▼ -28.9%on this news· ran to -44% by day 3
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Glucotrack, Inc. has announced the pricing of a public offering of 2.6 million shares at $1.15 per share, aiming to raise around $3.0 million. This offering is facilitated by Dawson James Securities and is expected to close on February 5, 2025, pending customary conditions. The proceeds are intended to support the company’s initiatives in developing novel technologies for diabetes management, particularly an implantable continuous blood glucose monitoring system. The offering comes under a registration statement declared effective by the SEC last year.
Read more →GCTK▼ -28.9%on this news· ran to -44% by day 3
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
Glucotrack, Inc. has announced the successful completion of its first human clinical study for a continuous blood glucose monitor (CBGM) placed in the subclavian vein. The study achieved its primary endpoint, showing no serious adverse events and establishing the safety of the sensor lead placement. This device, designed for three years of continuous monitoring, promises to be less intrusive than traditional options. Both the company and external experts express optimism about the technology's potential in diabetes management.
Read more →GCTK▼ -24.1%on this news· ran to -57% by day 3shared move
Glucotrack Announces Reverse Stock Split
Glucotrack, Inc. has announced a 1-for-20 reverse stock split effective February 4, 2025, following stockholder approval. This move aims to help the company comply with the Nasdaq's $1.00 minimum bid price requirement and may make the stock more appealing to institutional investors. The number of outstanding shares will decrease significantly, but existing ownership percentages will remain largely unaffected. However, the necessity of the split raises concerns about the company's current market viability and future compliance with exchange regulations.
Read more →GCTK▼ -24.1%on this news· ran to -57% by day 3shared move
GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT 1-for-20 reverse stock split to become effective as of the opening of trading on
Glucotrack, Inc. announced a 1-for-20 reverse stock split, effective February 4, 2025. This move follows approval from stockholders and aims to help the company meet Nasdaq's minimum bid price requirements. Following the split, the number of outstanding shares will decrease significantly, yet stockholder percentages will remain unchanged. The decision is also expected to make stock prices more appealing to institutional investors.
Read more →GCTKGlucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
Glucotrack, Inc. has appointed Peter C. Wulff as its new Chief Financial Officer, effective immediately. Wulff brings over 35 years of experience in financial management within the life sciences sector, having previously held CFO roles at various notable companies. His expertise is expected to support Glucotrack's growth as it moves forward with the development of its continuous blood glucose monitor technology. CEO Paul V. Goode highlighted Wulff's track record in capital markets as a significant asset for the company's strategic objectives.
Read more →GCTK▲ +47.2%on this news
GLUCOTRACK Announces ISO 13485:2016 certification ISO Certification highlights commitment to quality for continuous blood glucose monitor Rutherford, NJ
Glucotrack, Inc. has announced the achievement of ISO 13485:2016 certification from the British Standards Institute, solidifying its commitment to quality in the development of its Continuous Blood Glucose Monitor. This certification indicates that Glucotrack has established and maintains a quality management system that meets rigorous global standards. The company is focused on advancing technologies for diabetes care, aiming to deliver high-quality medical devices to improve patient outcomes.
Read more →GCTK▲ +47.2%on this news
Glucotrack Announces ISO 13485:2016 Certification
Glucotrack, Inc. has announced its receipt of ISO 13485:2016 certification from the British Standards Institute, marking a significant quality milestone for the company. This certification indicates that Glucotrack has established a quality management system in line with international standards for the design and development of medical devices. The company continues to focus on its Continuous Blood Glucose Monitor, which aims to enhance glucose monitoring for diabetes patients. This achievement underscores Glucotrack's dedication to regulatory excellence as it pursues further clinical and developmental milestones.
Read more →GCTK▼ -35.2%on this newsshared move
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
Glucotrack, Inc. has appointed Ted Williams as the new Vice President of Regulatory Affairs, bringing with him extensive experience in managing regulatory pathways for complex medical devices. Williams' leadership is anticipated to assist Glucotrack as it progresses in developing its Continuous Blood Glucose Monitor (CBGM) technology and navigating the FDA approval process. The company aims to enhance its strategic regulatory program at a critical development stage. This move underscores Glucotrack's ongoing commitment to improving diabetes management solutions.
Read more →GCTK▼ -10.5%on this news· ran to -25% by day 1
Glucotrack to Present at TechBio Showcase™ 2025
Glucotrack, Inc. announced its participation in the TechBio Showcase 2025, where CEO Paul V. Goode will present an update on the company's Continuous Blood Glucose Monitor. The event is part of the larger Biotech Showcase, which facilitates networking between biotechnology companies and investors. Glucotrack is focused on developing innovative solutions for diabetes management.
Read more →GCTKGlucotrack to Present at TechBio Showcase™ 2025
Glucotrack, Inc. (Nasdaq: GCTK) announced its participation in the TechBio Showcase 2025, where CEO Paul V. Goode will present an update on their Continuous Blood Glucose Monitor (CBGM). The event is part of the larger Biotech Showcase and is aimed at connecting biotechnology companies with investors and executives. Glucotrack focuses on creating innovative technologies for diabetes management, including a long-term implantable monitoring system.
Read more →GCTKGLUCOTRACK TO PRESENT AT TECHBIO SHOWCASE 2025 Presentation to feature an update on the Company's novel continuous blood glucose monitor for patients with diabetes Rutherford, NJ
Glucotrack, Inc. (Nasdaq: GCTK) announced its participation in the TechBio Showcase 2025, where CEO Paul V. Goode will provide an update on the company's novel continuous blood glucose monitor for diabetes. This presentation aims to highlight advancements in their long-term implantable glucose monitoring system, which minimizes the need for on-body wearable components. The showcase, part of Biotech Showcase 2025, will gather industry executives and investors to discuss further developments in biotechnology. Glucotrack is focusing on delivering innovative solutions for diabetes management, although it faces challenges related to regulatory approvals and funding.
Read more →GCTKGLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
Glucotrack, Inc. has announced the start of enrollment for a human clinical study focusing on its novel continuous blood glucose monitor (CBGM) for diabetes patients. The study will evaluate the CBGM's ability to provide real-time blood glucose readings and will take place over four days in a hospital setting. Data from this feasibility study is expected to be available in 6-8 weeks. Glucotrack's innovative device sets itself apart by measuring glucose directly from blood and is aimed at enhancing patient experience in diabetes management.
Read more →GCTKGlucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt
Glucotrack, Inc. has announced the successful closing of a $10 million public offering, which included the sale of common stock and warrants. Additionally, the company completed a private placement to convert $4 million in outstanding debt into equity on similar terms as the public offering. The news indicates the company's ongoing efforts to bolster its financial standing, aimed at supporting its development of technologies for diabetes management.
Read more →GCTKGlucotrack, Inc. Announces Pricing of $10.0 Million Public Offering
Glucotrack, Inc. has announced a public offering of approximately 7.2 million shares of common stock, expected to generate about $10 million before expenses. Each share will be accompanied by two series of common warrants priced at $1.81 each. The offering is set to close on or around November 14, 2024, subject to customary closing conditions. Additionally, a concurrent private placement will convert approximately $4 million in secured convertible notes into equity under similar terms.
Read more →GCTKGLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE
Glucotrack, Inc., a medical technology firm specializing in diabetes management, will participate in the 2024 BioFuture Conference in New York City from October 28-30, 2024. CEO Paul V. Goode will present an update on their continuous blood glucose monitor on October 29. The conference will showcase over 100 presentations, covering various future healthcare topics. Attendees will gain insights from industry leaders and discuss the convergence of biopharma and digital health innovations.
Read more →GCTKGLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING
Glucotrack, Inc. announced that it will present updated preclinical data for its continuous blood glucose monitor at the 24th Annual Diabetes Technology Meeting in October 2024. The presentation will be delivered by Dr. Mark Tapsak, showcasing the device's ability to measure glucose levels accurately without the typical lag time. Additionally, two posters detailing further studies will be available during the conference.
Read more →GCTKGLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING
Glucotrack, Inc. (GCTK) announced the presentation of updated preclinical data for its continuous blood glucose monitor (CBGM) at the upcoming 2024 Diabetes Technology Meeting in Burlingame, California. Dr. Mark Tapsak will deliver an oral presentation on the technology behind the CBGM, emphasizing its accurate measurement capabilities without lag time. Two additional posters will be presented at the conference, showcasing novel research in glucose monitoring. Glucotrack's innovative technology aims to offer a long-term solution for diabetes management.
Read more →GCTKJOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS
Glucotrack, Inc. has appointed John Ballantyne, PhD, to its Board of Directors, effective immediately. Ballantyne, a seasoned biotech executive with over 20 years of experience, is expected to contribute to the company's efforts in commercializing its novel continuous blood glucose monitoring technology. His extensive background in healthcare research and innovation will be invaluable as Glucotrack aims to enhance its strategic growth.
Read more →GCTKJOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS Biotech veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with di
Glucotrack, Inc. has announced the appointment of John Ballantyne, PhD, to its Board of Directors. Ballantyne, a biotech veteran with over 20 years of experience, is expected to aid in the company's efforts to commercialize its continuous blood glucose monitoring technology designed for diabetes management. His background in driving healthcare research and innovation is seen as a valuable asset for Glucotrack's strategic growth and mission advancement. The company continues to develop a long-term implantable glucose monitoring system.
Read more →GCTKGLUCOTRACK ANNOUNCES NEW VICE PRESIDENT OF CLINICAL OPERATIONS
Glucotrack, Inc. has appointed Sandie Martha as Vice President of Clinical Operations, enhancing its leadership team. With over 20 years of experience in clinical research, Martha will oversee the execution of the company’s Clinical Trial Program for its continuous blood glucose monitor (CBGM). This initiative aims to provide innovative technology to improve diabetes management. Under her leadership, Glucotrack plans to embark on human clinical trials to bring this technology to market.
Read more →GCTKGlucotrack’s Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference
Glucotrack, Inc. announced promising findings from a survey presented at the ADCES 2024 Annual Conference regarding its Continuous Blood Glucose Monitor (CBGM) concept. Over 50% of respondents indicated willingness to adopt this innovative technology, which provides continuous monitoring without the hassles of traditional systems. The study, featuring 757 participants with insulin-requiring diabetes, highlighted high interest in key features such as long sensor life and real-time readings. The company also documented successful preclinical studies that validate the accuracy and feasibility of its CGM technology.
Read more →GCTKGLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE
Glucotrack, Inc. will present its market research data regarding its Continuous Blood Glucose Monitor (CBGM) at the ADCES 2024 Annual Conference. This poster presentation highlights the interest and acceptance of glucose monitoring options among individuals with diabetes. CEO Paul V. Goode anticipates sharing valuable insights with the diabetes care community. The findings will subsequently be available on Glucotrack's website.
Read more →GCTKGLUCOTRACK ANNOUNCES NEW FUNDING FOR DEVELOPMENT OF ITS CONTINUOUS BLOOD GLUCOSE MONITOR
Glucotrack, Inc. announced its successful acquisition of $4 million in funding aimed at supporting the development of its Continuous Blood Glucose Monitor (CBGM). This funding, provided by major shareholder John Ballantyne, will finance the upcoming First in Human clinical trial, signifying a notable step forward in the company's ongoing innovation efforts. CEO Paul V. Goode highlighted the positive impact of the financial support on their plans for a less burdensome glucose monitoring method for diabetes patients. This investment emphasizes the potential of Glucotrack's technology in addressing significant market needs.
Read more →GCTKGLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS
Glucotrack, Inc. has appointed Andy Balo to its Board of Directors, effective immediately. Balo brings over 20 years of experience from Dexcom, where he played a key role in glucose monitoring technology advancements. His expertise in regulatory and clinical strategies is expected to support Glucotrack's development of a long-term implantable continuous blood glucose monitoring system. Balo expressed enthusiasm about contributing to the growth of Glucotrack's groundbreaking technology for diabetes care.
Read more →GCTKGLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR
Glucotrack, Inc. announced the successful completion of a 60-day long-term preclinical study for its implantable continuous glucose monitor. The study confirmed the sensor's feasibility for glucose monitoring in the epidural space, showing that it performed well against both a blood glucose monitor and a subcutaneous CGM. No adverse clinical signs were observed, and the device demonstrated durability over the study period. The company aims to continue developing this technology to benefit individuals living with diabetes, particularly those suffering from painful diabetic neuropathy.
Read more →GCTKE xhibit 99.1 GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR Completion of the novel epidural continuous glucose monitoring study confirms
Glucotrack, Inc. reported the successful completion of a 60-day long-term preclinical study of its epidural continuous glucose monitoring sensor. This study confirmed the feasibility of monitoring glucose levels through an implanted sensor in the epidural space without any adverse clinical effects. The findings suggest that the device may offer significant advantages for patients with diabetic neuropathy, reinforcing Glucotrack's commitment to innovative diabetes management solutions. As a result, the company is optimistic about further developing this technology.
Read more →GCTKGLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE
Glucotrack, Inc. (Nasdaq: GCTK) will showcase its innovations at the Sidoti Small Cap Investor Conference on June 12, 2024, with CEO Paul V. Goode presenting. The company is focusing on the development of a long-term implantable continuous blood glucose monitoring system aimed at improving the lives of people with diabetes. Their technology promises sensor longevity exceeding two years without requiring a wearable component. While the participation in the conference could enhance visibility and attract investment, there are notable risks including dependence on regulatory approvals and capital raising efforts.
Read more →GCTKGLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
Glucotrack, Inc. (GCTK) announced promising results from its second long-term preclinical study for a Continuous Blood Glucose Monitor (CBGM), demonstrating a Mean Absolute Relative Difference (MARD) of 4.7% at Day 90. This device aims to revolutionize glucose monitoring by providing real-time blood glucose measurements without the lag associated with existing methods. The study concluded with no significant adverse effects and validated the device's sustained accuracy. Glucotrack plans to initiate human clinical trials later this year, pursuing further advancements in diabetes management technology.
Read more →GCTKGLUCOTRACK’S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDY
Glucotrack, Inc. has reported positive results from a 30-day preclinical study of its implantable continuous glucose monitoring sensor, which was successfully implanted in animals. The sensor demonstrated reliable glucose tracking in the epidural space, matching the performance of traditional subcutaneous continuous glucose monitors. This study builds on previous acute testing results and indicates a promising future for diabetes management technology. The ongoing 60-day study will further assess the long-term viability of this monitoring approach.
Read more →GCTKGLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT
Glucotrack, Inc. has announced a 1-for-5 reverse stock split effective May 20, 2024, to address compliance with the $1.00 minimum bid price for Nasdaq listing. This will reduce the total number of outstanding shares from approximately 27.39 million to about 5.48 million, while the ownership percentage of stockholders will remain unchanged, except for fractional shares. The company's stock will continue trading under the ticker 'GCTK' on the Nasdaq Capital Market.
Read more →GCTKGLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT 1-for-5 reverse stock split to become effective as of the opening of trading on
Glucotrack, Inc. has announced a 1-for-5 reverse stock split, effective as of May 20, 2024, to comply with Nasdaq's minimum bid price requirement. The decision follows approval from the company's stockholders during the annual meeting held on April 26, 2024. The reverse split is intended to enhance the attractiveness of the stock for institutional investors. However, uncertainties remain about the effectiveness of this measure in ensuring compliance with listing standards.
Read more →GCTKGLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION
Glucotrack, Inc. (Nasdaq: GCTK) announces that two of its abstracts will be presented at the 84th Scientific Sessions of the American Diabetes Association from June 21-24, 2024, in Orlando, FL. The presentations will focus on preclinical data and sensor longevity modeling of their Continuous Blood Glucose Monitor (CBGM). This event is a notable platform for advancements in diabetes research, enabling researchers and healthcare professionals to share insights. The poster session details include an evaluation of a long-term implantable CGM and an in silico modeling investigation involving a partnership with TTP.
Read more →GCTKGLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENT
Glucotrack, Inc. has announced the successful closure of a private placement of securities, raising $500,000 through the issuance of 396,825 common shares at $1.26 each. The transaction was conducted without warrants or commissions and is aimed at financing the company's growth initiatives and general working capital. This development reflects a commitment from both executive management and existing shareholders to support the company's future projects, including ongoing advancements in diabetes management technology.
Read more →GCTKGLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING
Glucotrack, Inc. has announced the expansion of its continuous glucose monitoring technology to include epidural glucose measurements aimed at treating patients with Painful Diabetic Neuropathy. This innovative approach may simplify device management and improve treatment outcomes for over 7 million individuals affected by this condition. The company's recent preclinical studies have shown promising results in tracking glucose levels effectively. Glucotrack's technology has completed successful animal testing and is now moving to a long-term study for further evaluation.
Read more →GCTKGLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
Glucotrack, Inc. has announced that its implantable Continuous Blood Glucose Monitor (CBGM) sensor may now last beyond three years, an improvement of one year from previous projections. This was determined through advanced computational modeling conducted with The Technology Partnership. The CBGM is designed to provide quick glucose monitoring without the 15-20 minute delays seen with current interstitial sensors. The collaboration is expected to advance Glucotrack's development program and pave the way for future innovations in diabetes management.
Read more →GCTKGLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY
Glucotrack, Inc. has appointed Vincent Wong as Vice President of Quality, bringing significant expertise in medical device manufacturing and quality management. Wong's responsibilities will include establishing the company's Quality System and leading efforts for ISO-13485 certification for its Continuous Blood Glucose Monitoring technology. This appointment is viewed positively as Glucotrack transitions towards human clinical trials and commercialization of its innovative diabetes management device.
Read more →GCTKGLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
Glucotrack, Inc. has selected Cirtec Medical Corp as its manufacturer for its implantable Continuous Blood Glucose Monitor (CBGM). This partnership aims to leverage Cirtec's expertise in implantable medical devices to facilitate the development and commercial manufacturing processes for the CBGM. The device promises a longevity of over two years and simplifies glucose monitoring for diabetes patients. The companies are set to begin first-in-human clinical studies later this year, marking a significant stride in the diabetes technology market.
Read more →GCTKGLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
GlucoTrack, Inc. has announced positive results from its first preclinical study of an implantable Continuous Blood Glucose Monitor (CBGM), achieving promising accuracy metrics and ensuring safety with no significant adverse events. The study demonstrated Mean Absolute Relative Difference (MARD) values of 8.1% at Day 30 and 4.5% at Day 60. The company is now moving forward to long-term preclinical testing and plans to initiate first-in-human studies later this year. The technology aims to offer continuous glucose monitoring with advantages over traditional systems.
Read more →GCTKGLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Glucotrack, Inc. has been granted an additional 180 days by Nasdaq to regain compliance with its minimum bid price requirement, extending the compliance deadline to May 20, 2024. The extension follows a notification indicating the company had not met the minimum $1.00 bid price requirement over 30 consecutive business days. The company will continue to trade under the GCTK symbol while pursuing compliance possibly through a reverse stock split. This situation highlights ongoing challenges in meeting stock price standards amidst market fluctuations.
Read more →GCTKE xhibit 99.1 GLUCOTRACK ANNOUNCES 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement Rutherford, NJ
Glucotrack, Inc. has been granted a 180-day extension by Nasdaq to comply with its minimum bid price requirement, allowing until May 20, 2024, for the company to regain compliance. This extension follows a notification that its stock did not meet the minimum price of $1.00 per share. Glucotrack plans to cure this deficiency, possibly through a reverse stock split, and currently retains trading eligibility on the Nasdaq Capital Market. The company is focused on developing glucose monitoring technologies aimed at diabetes management.
Read more →GCTKGLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE
Glucotrack, Inc. (GCTK) has announced a strategic shift towards continuous glucose monitoring (CGM) technologies to enhance its market presence in diabetes management. In response to new clinical guidelines questioning the value of traditional blood glucose monitoring for non-insulin-using type 2 diabetes patients, the company aims to refine its focus on implantable CGM devices. Recent advancements in their development program, including successful feasibility studies, position them favorably for regulatory approval. Glucotrack acknowledges the evolving landscape of diabetes care, indicating a promising commercial opportunity for CGMs amid the decline of non-invasive solutions.
Read more →GCTKGLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
Glucotrack, Inc. has begun preclinical animal testing for its implantable continuous glucose monitor (CGM), marking an important step in its development. The company previously reported positive feasibility study results, showing that their CGM sensor can function for a minimum of two years post-implant. Early findings indicate the implant procedure is quick, taking 15-20 minutes, and has shown no short-term or long-term adverse effects in animal subjects. Glucotrack plans to conduct long-term performance studies starting in late Q4 2023.
Read more →GCTKGLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS
Glucotrack, Inc. has announced the appointment of Erin Carter to its Board of Directors and as Chair of its Audit Committee. With over 30 years of experience in the medical device industry, particularly with companies like Medtronic and Boston Scientific, Carter is expected to provide valuable financial insight and strategic guidance. Her recruitment comes at a critical time as Glucotrack prepares to advance its mission in glucose monitoring technologies for diabetes patients. CEO Paul Goode expressed confidence in her ability to help grow the organization and enhance shareholder value.
Read more →GCTKGLUCOTRACK ANNOUNCES NEW VP OF MARKETING
Glucotrack, Inc. has appointed Drinda Benjamin as the new Vice President of Marketing. With over 20 years of experience in health technology commercialization, she aims to lead the company's go-to-market strategies and enhance its marketing operations. Benjamin previously held significant roles at Intuity Medical and Senseonics, and she is expected to play a critical role in advancing Glucotrack's product development in glucose monitoring technologies. The company remains focused on introducing non-invasive solutions to improve the lives of people with diabetes.
Read more →GCTKGLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
Glucotrack, Inc. announced the positive results of its feasibility study for an implantable continuous glucose monitor (CGM) aimed at Type 1 and Type 2 diabetes patients. The study demonstrated that the CGM sensor design could potentially provide reliable glucose measurements for at least two years post-implant. The results indicate a significantly longer sensor longevity than current offerings, leading the company to prepare for upcoming long-term animal studies. CEO Paul Goode expressed confidence in the technology's potential to enhance the quality of life for diabetes patients.
Read more →GCTKGlucoTrack Closes $10 Million Underwritten Public Offering of Common Stock
GlucoTrack, Inc. has successfully completed a firm commitment underwritten public offering, generating approximately $10 million in gross proceeds. The offering involved the sale of over 7 million shares of common stock at a price of $1.36 per share. The company intends to allocate the net proceeds towards working capital, general corporate purposes, and potential acquisitions. Aegis Capital Corp. served as the sole book-running manager for this offering.
Read more →GCTKGLUCOTRACK, INC. UNDERWRITING AGREEMENT New York, New York
GlucoTrack, Inc. has finalized an underwriting agreement with Aegis Capital Corp. to issue common stock and pre-funded warrants. This agreement marks a significant step in the company's financing strategy, allowing it to raise capital through securities. The underwriting involves specified quantities of shares and warrants, set at competitive pricing. Additionally, GlucoTrack has filed a registration statement with the SEC, ensuring compliance with regulatory requirements.
Read more →GCTKGlucoTrack Announces Pricing of $10 Million Underwritten Public Offering of Common Stock
GlucoTrack, Inc. has announced the pricing of a public offering of common stock aimed at raising approximately $10 million. The offering will consist of over 7.3 million shares priced at $1.36 each, with proceeds intended for working capital and corporate purposes, including possible acquisitions. The offering is set to close on April 17, 2023, subject to regulatory conditions. Aegis Capital Corp. is facilitating the offering as the sole book-running manager.
Read more →GCTKGlucoTrack Announces Proposed Underwritten Public Offering of Common Stock
GlucoTrack, Inc. announced its intention to conduct an underwritten public offering of common stock, intending to use the proceeds for working capital and various corporate purposes. This includes potential acquisitions and sales and marketing activities. The offering is subject to market conditions, and the company has not guaranteed the completion, size, or terms of the offering. Aegis Capital Corp. will act as the sole book-running manager for the offering.
Read more →GCTKGLUCOTRACK PROVIDES SHAREHOLDER UPDATE
GlucoTrack, Inc. provided a shareholder update detailing progress and future plans. The company has made strides in developing its non-invasive glucose monitoring device and is working on miniaturizing the technology for better user experience and accuracy. With a new clinical prototype featuring enhanced capabilities, GlucoTrack is also exploring opportunities in implantable continuous glucose monitors. While promising, challenges such as sensor placement and regulatory standards are areas of concern as the company moves forward.
Read more →GCTKGLUCOTRACK ANNOUNCES THE HIRING OF DR. MARK TAPSAK
INDUSTRY VETERAN TO LEAD NEW CONTINUOUS GLUCOSE MONITORING R&D PROGRAM Rutherford, NJ, Oct. 14, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, ann
Read more →GCTKGLUCOTRACK TO BEGIN RESEARCH & DEVELOPMENT OF NOVEL CONTINUOUS GLUCOSE MONITORING SYSTEM
Rutherford, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today it is expanding its pr
Read more →GCTKGlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor
Rutherford, NJ and Or Yehuda, Israel, June 22, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today
Read more →GCTKGlucoTrack, Inc. Announces Effectiveness of Corporate Name Change and Ticker Symbol Change
To begin trading under the Nasdaq Symbol GCTK Rutherford, NJ and Or Yehuda, Israel, March 14, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), formerly known as Integrity Applications, Inc., (Nasdaq: IGAP), innovator of GlucoTrack®, a non
Read more →GCTKNew Independent Director Brings Significant Public Company Leadership And Corporate Governance Experience Wilmington, DE and Ashdod, Israel
Independent Director Brings Significant Public Company Leadership And Corporate Governance Experience DE and Ashdod, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) - Integrity Applications, Inc. (www.integrity-app.com) (IGAP), innovator of GlucoTrack , a non-invasive device for measuri
Read more →GCTKCONSULTING AGREEMENT This CONSULTING AGREEMENT ("Agreement"), dated as of
CONSULTING AGREEMENT ("Agreement"), dated as of August 1, 2019, is entered into by and between Integrity Applications, Inc. ("Company") and Jolie Kahn ("Consultant"). 1. Work to be Performed. 1.1 Consultant shall provide strategic planning and advisory services including, but
Read more →GCTKIntegrity Applications Signs Distribution Agreement for Its GlucoTrack Glucose Monitoring Device in the Nordic Countries Wilmington, DE and Ashdod, Israel
Applications Signs Distribution Agreement for Its GlucoTrack Glucose Monitoring Device in the Nordic Countries DE and Ashdod, Israel, July 25, 2018 (GLOBE NEWSWIRE) - Integrity Applications, Inc. (www.integrity-app.com) (OTCQB: IGAP) ("Integrity" or "Integrity Applications") an
Read more →Competitive Position
How GCTK ranks across every disease it competes inCompetitive Position is a premium feature
See how GCTK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial